The latest developments and news items regarding our portfolio stocks that you should know about. Read More
Benjamin Shepherd is a recognized exchange-traded fund (ETF), mutual fund and stock expert with an extensive background analyzing time-tested funds, including their managers and strategies. Ben looks for investments that have proven themselves in both bull and bear markets. Ben also specializes in covering emerging markets, pinpointing the most dynamic investments in developing nations for market-beating growth.
Ben is an analyst for Global Income Edge and regularly contributes to Personal Finance, Investing Daily’s flagship product.
Analyst Articles
The latest developments and news items regarding our portfolio stocks that you should know about. Read More
- April 28, 2016
-
Download Issue
Express turns around by targeting young professionals instead of fickle teens. Read More
[from the 04/25/2016 edition of Breakthrough Tech Weekly]Nimble Storage (NYSE: NMBL), which designs and sells a flash-optimized data storage platform, has been absolutely crushed so far this year. Shares have fallen by more than 14% after a couple of disappointing quarters.The company believed its products would revolutionize the data… Read More
[from the 04/25/2016 edition of Breakthrough Tech Weekly]Nimble Storage (NYSE: NMBL), which designs and sells a flash-optimized data storage platform, has been absolutely crushed so far this year. Shares have fallen by more than 14% after a couple of disappointing quarters.The company believed its products would revolutionize the data… Read More
Last week Argos Therapeutics (ARGS) announced its COO was abruptly resigning and the company known for treating aggressive forms of cancer with immunotherapy would lay off 18 lab workers. The share price immediately plunged as a result, falling from more than $12 to below $8 in a matter of days.As… Read More
Last week Argos Therapeutics (ARGS) announced its COO was abruptly resigning and the company known for treating aggressive forms of cancer with immunotherapy would lay off 18 lab workers. The share price immediately plunged as a result, falling from more than $12 to below $8 in a matter of days.As… Read More
Last week Argos Therapeutics (ARGS) announced its COO was abruptly resigning and the company known for treating aggressive forms of cancer with immunotherapy would lay off 18 lab workers. The share price immediately plunged as a result, falling from more than $12 to below $8 in a matter of days.As… Read More
The economic experts, and the bookmakers, say it isn’t likely. Read More
The economic experts, and the bookmakers, say it isn’t likely. Read More